A portfolio company of Sadé
The world’s most effective medical cannabis formulations for the treatment of inflammation-related conditions
PlantEXT is on a mission to unlock the anti-inflammatory benefits of medical cannabis through the company’s proprietary research and technology platform. As an early mover in medical cannabis research and a global leader in the development of medical cannabis products, PlantEXT’s innovative activities are backed by advanced science and clinical studies in Israel.
Adopting a true pharma approach to cannabis development, all of PlantEXT’s research is conducted in a quality-controlled laboratory, run by Dr. Hinanit Koltai, a world leader in medical cannabis research.
PlantEXT is currently headed by Douglas Sommerville, a Canadian pharma industry veteran, whose prior field experience extends to serving as the Head of Teva Canada, a branch of the leading Israeli generic drug producer, Teva, During Doug’s 14-year tenure, Teva Canada recorded record profits and became strongly positioned as a market leader.
PlantEXT In The News:
Check out top stories and leading news updates highlighting the leading Canadian pharmaceutical cannabis innovator, PlantEXT.
A True Pharma Approach to Cannabis
Product development focused on treatment for diseases and conditions caused by inflammatio
Fully permitted and equipped independent laboratory facilities in Tel Aviv
Dedicated and highly qualified PlantEXT researchers, trained at leading cannabis research facilities in Israel
R&D plans: Expansion of IBD clinical studies; development of IP and products for pain, dermatological conditions and other inflammatory conditions
Evidence-based clinical support for products
Speed to market: Streamlined cannabis regulatory pathway compared to traditional pharma